Vaughn Himes Net Worth

The estimated Net Worth of Vaughn B Himes is at least $22.9 Milione dollars as of 9 November 2023. Vaughn Himes owns over 8,785 units of Seagen Inc stock worth over $9,743,486 and over the last 16 years he sold SGEN stock worth over $9,176,349. In addition, he makes $3,951,390 as Chief Technical Officer at Seagen Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Vaughn Himes SGEN stock SEC Form 4 insiders trading

Vaughn has made over 61 trades of the Seagen Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 8,785 units of SGEN stock worth $1,874,016 on 9 November 2023.

The largest trade he's ever made was exercising 40,500 units of Seagen Inc stock on 15 December 2015 worth over $373,815. On average, Vaughn trades about 5,942 units every 47 days since 2009. As of 9 November 2023 he still owns at least 42,574 units of Seagen Inc stock.

You can see the complete history of Vaughn Himes stock trades at the bottom of the page.

Vaughn Himes biography

Dr. Vaughn B. Himes serves as Chief Technical Officer of the Company. Dr. Himes joined Seattle Genetics as Executive Vice President, Technical Operations in April 2009 and served as our Executive Vice President, Technical Operations and Process Science from July 2012 until August 2016. Previously, Dr. Himes was with ZymoGenetics, Inc. from November 2005 to March 2009, most recently as Senior Vice President, Technical Operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development. From March 2003 to October 2005, he was Vice President, Manufacturing at Corixa, Inc. Prior to that, he held Vice President positions in manufacturing and development at Targeted Genetics and Genovo, Inc. Dr. Himes received a B.A. in Chemistry from Pomona College in California and a Ph.D. in Chemical Engineering from the University of Minnesota.

What is the salary of Vaughn Himes?

As the Chief Technical Officer of Seagen Inc, the total compensation of Vaughn Himes at Seagen Inc is $3,951,390. There are 4 executives at Seagen Inc getting paid more, with Clay Siegall having the highest compensation of $14,521,500.

How old is Vaughn Himes?

Vaughn Himes is 59, he's been the Chief Technical Officer of Seagen Inc since 2016. There are 9 older and 8 younger executives at Seagen Inc. The oldest executive at Seagen Inc is Marc Lippman, 75, who is the Independent Director.

Insiders trading at Seagen Inc

Over the last 22 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro... e Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.

What does Seagen Inc do?

seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys

Complete history of Vaughn Himes stock trades at Seagen Inc, VBI Vaccines e Achieve Life Sciences

Seagen Inc executives and stock owners

Seagen Inc executives and other stock owners filed with the SEC include:

• Clay Siegall,
  Chairman of the Board, President, Chief Executive Officer
• Roger Dansey,
  Chief Medical Officer
• Todd Simpson,
  Chief Financial Officer
• Jean Liu,
  Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
• Vaughn Himes,
  Chief Technical Officer
• Dr. Clay B. Siegall,
  Co-Founder, Chairman, Pres & CEO
• Dr. Roger D. Dansey M.D.,
  Chief Medical Officer & Interim CEO
• Jean I. Liu,
  Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec.
• Jean I. Liu J.D., M.S.,
  Chief Legal Officer
• Charles R. Romp,
  Exec. VP of Commercial U.S.
• Todd E. Simpson,
  Chief Financial Officer
• Felix Baker,
  Lead Independent Director
• David Gryska,
  Independent Director
• John Orwin,
  Independent Director
• Nancy Simonian,
  Independent Director
• Alpna Seth,
  Independent Director
• Daniel Welch,
  Independent Director
• Marc Lippman,
  Independent Director
• Ted Love,
  Director
• David Caouette,
  VP of Corp. Communications
• Dr. Vaughn B. Himes,
  Chief Technical Officer
• Christopher P. Pawlowicz,
  Exec. VP of HR
• Matt Skelton,
  VP of Marketing
• Natasha A. Hernday,
  Exec. VP of Corp. Devel. & Alliance Management
• Nancy Whiting B.Sc., Pharm.D.,
  Exec. VP of Corp. Strategy, Alliances & Communications
• Peggy Pinkston,
  VP of Investor Relations
• Bros. Advisors Lp Baker Bro...,
  
• Bros. Advisors Lp Baker Bro...,
  
• Felixbaker Julian Baker Bro...,
  
• Srinivas Akkaraju,
  Director
• Eric Dobmeier,
  Vice President,
• Bros. Advisors Lp667, L.P.B...,
  
• Sandra M Swain,
  
• Morgan Partners Bhca Lpjpmp...,
  
• / Tisch Capital (Gp), Llcba...,
  
• Biotech Capital (Gp), Llcba...,
  
• Robin G Taylor,
  Chief Commercial Officer
• Felix667, L.P.Baker Julian ...,
  
• John Peter Mclaughlin,
  Director
• Felix Baker,
  Director
• Morris Rosenberg,
  SVP, Development
• Bruce J. Seeley,
  EVP, Commerical
• Felix667, L.P.Baker Brother...,
  
• Thomas C Reynolds,
  Chief Medical Officer
• Christopher S. Boerner,
  SVP, Commercial
• Brothers Life Sciences Capi...,
  
• Capital (Gp), Llcbaker Juli...,
  
• Holdings, Inc.H&Q Employee ...,
  
• Bros. Capital (Gp), Llcbake...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• Darren S Cline,
  SVP, Commercial
• Morgan Partners Bhca Lpjpmp...,
  
• Felixbaker Julian Baker Bro...,
  
• Franklin M Berger,
  Director
• Morgan Partners Bhca Lp Jp,
  10% owner
• Daniel Floyd Jr Hoth,
  Director
• Morgan Partners Bhca Lpjpmp...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Jonathan Gallen,
  10% owner
• Management Partners Vi Llcd...,
  
• Pamela A Trail Smith,
  Chief Scientific Officer
• Brothers Life Sciences Capi...,
  
• Biotech Capital Ii Gp Llcba...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Morgan Partners Bhca Lpjpmp...,
  
• Biotech Capital Ii (Z) (Gp)...,
  
• Amy Sing,
  Sr. Director Medical Affairs
• Michael Powell,
  Director
• Biotech Capital Iii (Z) (Gp...,
  
• Tim Carroll,
  CFO
• Investment Llc Cascade,
  
• Douglas Southern,
  Director
• Karl Erik Hellstrom,
  Director
• Michael Mcdonald,
  Chief Medical Officer
• Morgan Partners Bhca Lpjpmp...,
  
• Peter Senter,
  Vice President, Chemistry
• H Perry Fell,
  Chairman
• Bros. Advisors Lp Baker Bro...,
  
• Bros. Advisors Lp667, L.P.B...,
  
• David R Epstein,
  CEO
• Charles R Romp,
  EVP, Commercial U.S.